1. Purified micelle containing one or more rabies virus (RV) glycoproteins (G-proteins) .2. The purified micelle according to claim 1, wherein the RV G protein is obtained from an RV strain isolated from a human, a dog, a bat, a raccoon, a skunk, and a fox. Virus-like particle (VLP) containing RV G protein. 4. VLP according to claim 3, where the RV G protein is obtained from an RV strain isolated from a human, a dog, a bat, a raccoon, a skunk and a fox. VLP according to claim 3, where the VLP contains a matrix (M) protein. VLP according to claim 5, wherein said M protein is derived from RV.7. VLP according to claim 5, wherein said M protein is an M1 protein from an influenza virus strain. VLP according to claim 5, where the specified strain of influenza virus is a strain of avian influenza virus. VLP of claim 8, where the specified strain of avian influenza virus is a strain of H5N1.10. VLP according to claim 9, wherein said H5N1 strain is A / Indonesia / 5 / 05.11. VLP according to claim 5, wherein said M protein is obtained from a Newcastle disease virus (NDV) strain. VLP according to any one of claims 3 to 11, wherein the VLP is expressed in a eukaryotic cell under conditions that allow the formation of VLP. VLP according to claim 12, wherein the eukaryotic cell is selected from the group comprising cells of yeast, insects, amphibians, birds, mammals or plants. An immunogenic composition comprising a purified micelle according to any one of claims 1 to 2.15. An immunogenic composition comprising VLP according to any one of claims 3-13.16. A pharmaceutically acceptable vaccine composition comprising a purified micelle according to any one of claims 1 to 2, wherein the micelle is capable of eliciting an immune response in the host organism. A pharmaceutically acceptable vaccine composition comprising a VLP according to any one of claims 3 to 13, wherein the VLP is capable of eliciting an immune response in the host. 18. A kit for immunizing a human subject against
